Screener
ADMA Biologics ADMA Operating Income
Operating Income at other companies
Other financials
Where this comes from
Reported directly by ADMA Biologics in its filing.
Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.
The source filing: ADMA Biologics’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 5:16 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001140361-26-031445
| Line item | Three Months ended June 30, 2026 | Three Months ended June 30, 2025 | Six Months ended June 30, 2026 | Six Months ended June 30, 2025 |
|---|---|---|---|---|
| Gain on sale of plasma centers | - | - | (7,980) | - |
| Selling, general and administrative | 26,737 | 22,214 | 53,479 | 46,292 |
| Total operating expenses | 33,832 | 24,429 | 56,308 | 50,645 |
| INCOME FROM OPERATIONS | 52,445 | 42,798 | 110,719 | 77,678 |
| OTHER INCOME (EXPENSE): | ||||
| Interest and other income | 1,238 | 400 | 2,331 | 1,008 |
| Interest expense | (3,424) | (1,834) | (5,524) | (3,809) |
| Loss on extinguishment of debt | - | (1,159) | - | (1,159) |
Item 1. Financial Statements.
FAQ
- What is ADMA Biologics's operating income?
- ADMA Biologics (ADMA) reported operating income of $52.45M in Q2 2026.
- How has ADMA Biologics's operating income changed year-over-year?
- ADMA Biologics's operating income increased by 22.5% year-over-year, from $42.8M to $52.45M.
- What is the long-term trend for ADMA Biologics's operating income?
- Over 4 years (2021 to 2025), ADMA Biologics's operating income has grown at a 34.6% compound annual growth rate (CAGR), from -$58.37M to $191.44M.
- What does operating income mean?
- Gross profit minus all operating expenses (SG&A, R&D, D&A). Measures the profit from core business operations before interest, taxes, and non-operating items.
Ask your AI about ADMA Biologics's operating income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude